The majority of new medicinal compounds developed for the treatment of cancer fail during the course of their development and pharmaceutical companies have moved in recent years to broadening the modalities and the range of sources from which potential compounds can be identified. As a result of this, there is opportunity for small biotech companies to develop leads for eventual sale to or partnering with pharmaceutical companies. This is particularly the case for novel drug discovery modalities or for biological targets that have proved untreatable by conventional drug discovery methodologies. One such area is the deployment of alkaloid molecules.
The current management structure of the SwaLife Biotech has two founder members. Duties and roles have been shared based on individual abilities and expertise. The CEO of the company will be Dr Pravin Badhe while Mr Basudev Paudyal will take CSO responsibilities.
has over 12 years of experience in Pharmaceutical field. He has expertise in target discovery and lead identification and has experience in drug repurposing in rare disease such as progeria. He is a Pharmacist and has PhD in life science. In PhD he has discover five novel small molecules from plants. He is an experience scientist and has got expertise in pharma wholesale, retail sales, marketing and general management. He has held number of positions
He is the co-founder of SwaLife Biotech. He has completed his BSc (Hons) Microbiology from University of West of England in 2009 and MSc Cancer Biology (2012) from Kingston University London and currently in the final year of his PhD in nanoparticles and their immune response from Kinston University London. He is responsible for research and
Two dynamic scientists came together to found SwaLife Biotech, a company that has developed a technology that isolates nine novel molecules from plants. These molecules enhance the skin DNA repair process, and with them the team has developed sunscreen, anti-aging cream, and skin repair cream.
Some months back, I ran into an old friend of mine who I don’t see often these days. After the usual chitchat formalities of family, work, and health, she took a special interest in my latest diabetic report (I have type 1 diabetes). Her husband, who was not long retired and still living a very active life, had been recently diagnosed with type 2 diabetes, although he was coping well with treatment.